{"product_id":"zynex-business-model-canvas","title":"Zynex Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZynex Business Model Canvas: Clarify Value, Revenue Drivers \u0026amp; Strategic Positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic framework behind Zynex's business model-this Business Model Canvas maps the company's value proposition, customer segments, key partnerships, and revenue streams to show how its electrotherapy and diagnostic solutions create durable growth and market relevance.\u003c\/p\u003e\n\u003cp\u003eIdeal for investors, consultants, and founders, the downloadable Word and Excel files deliver a practical, section-by-section analysis to assess monetization, benchmark strategy, support due diligence, and uncover opportunities-access the full canvas to dive deeper.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird-Party Insurance Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex depends on partnerships with private insurers and government payers to secure device reimbursement; in 2024 roughly 62% of its revenue tied to reimbursed services, so coverage policies directly affect patient access. Zynex keeps a broad payer network-over 1,200 contracted plans as of Q4 2024-to lower patient out-of-pocket costs and support uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhysicians, physical therapists, and orthopedic surgeons prescribe Zynex electrotherapy devices, supplying clinical validation that helped drive Zynex Medical's 2024 revenue of $162.3M and 18% year-over-year growth; the company sustains these partnerships via clinician education programs and by sharing real-world outcome data showing pain-score reductions and compliance metrics from \u0026gt;40,000 treated patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing Component Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic vendors supply high-grade electronic components and raw materials for Zynex's electrotherapy units, with 95% of parts sourced from ISO 13485 or ISO 9001-certified suppliers to meet medical standards; reliable partnerships cut stockout risk, which industry data shows can save up to 12% of production costs and prevent revenue losses from delayed shipments-Zynex vets suppliers for regulatory compliance (FDA\/CE) and quarterly quality audits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Compliance Consultants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company works with FDA and international certification consultants to clear devices faster; in 2025 Zynex reported R\u0026amp;D and regulatory spend of about $18.7M, and these partners cut approval timelines by an estimated 20-30% for complex neurology products.\u003c\/p\u003e\n\u003cp\u003eThese consultants verify safety standards across new neurological diagnosis and monitoring devices, reducing recall and noncompliance risk as Zynex broadens its product portfolio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 regulatory\/R\u0026amp;D spend ≈ $18.7M\u003c\/li\u003e\n\u003cli\u003eApproval time reduction ~20-30%\u003c\/li\u003e\n\u003cli\u003eLowered recall\/noncompliance risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZynex partners with regional distributors to enter markets outside the United States, leveraging local regulatory expertise to navigate approvals and reimbursement; in 2024 international sales represented about 12% of Zynex's $143.6M revenue, showing the model's scale.\u003c\/p\u003e\n\u003cp\u003eDistributors handle logistics, sales, and localized marketing, letting Zynex avoid a large direct international sales force and keeping SG\u0026amp;A growth lower while expanding reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $143.6M; international ~12%\u003c\/li\u003e\n\u003cli\u003eReduces need for direct hires and capex\u003c\/li\u003e\n\u003cli\u003eLocal partners manage regulatory, logistics, marketing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZynex's partner network fuels 62% reimbursement exposure and 18% clinician-driven growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex relies on payer contracts (≈1,200 plans, 62% revenue tied to reimbursement in 2024), clinician prescribers (driving $162.3M revenue in 2024, 18% YoY growth), certified suppliers (95% parts from ISO 13485\/9001 vendors), regulatory consultants (2025 R\u0026amp;D\/regulatory ≈$18.7M; approval time -20-30%), and regional distributors (international ≈12% of 2024 revenue).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer contracts\u003c\/td\u003e\n\u003ctd\u003ePlans \/ revenue exposure\u003c\/td\u003e\n\u003ctd\u003e≈1,200 \/ 62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians\u003c\/td\u003e\n\u003ctd\u003eRevenue \/ YoY\u003c\/td\u003e\n\u003ctd\u003e$162.3M \/ 18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers\u003c\/td\u003e\n\u003ctd\u003eCertified parts\u003c\/td\u003e\n\u003ctd\u003e95% ISO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory consultants\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D \u0026amp; regulatory spend \/ approval impact\u003c\/td\u003e\n\u003ctd\u003e$18.7M \/ -20-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003eInternational revenue\u003c\/td\u003e\n\u003ctd\u003e≈12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Zynex detailing customer segments, channels, value propositions, revenue streams, key resources, partners, activities, cost structure, and customer relationships with strategic insights and SWOT-linked competitive advantages for presentations and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable Business Model Canvas that condenses Zynex's strategy into a one-page snapshot, saving hours of setup and enabling quick comparison, team collaboration, and boardroom-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex's R\u0026amp;D drives continuous innovation in non-invasive electrotherapy, targeting miniaturization, 30% better battery life and cloud-enabled digital monitoring after 2024 trials; R\u0026amp;D spend was $18.2M in FY2024 (9.6% of revenue) to expand into neurology and wound care, keeping it competitive vs. pharma pain meds by lowering device cost-per-treatment and improving patient adherence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-House Manufacturing and Assembly\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex runs in-house manufacturing and assembly near its Englewood, Colorado headquarters, assembling devices like the NexWave and packaging disposables to control quality and inventory; in 2024 internal production supported ~60% of unit output, helping keep lead times under 10 days and reducing inventory turns to 6.2 per year so they can pivot quickly to demand or design changes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales and Physician Outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpzynex hires a high-touch direct sales force that as of fy2024 drove device prescriptions by educating clinicians on electrotherapy benefits versus opioids reps logged clinic visits in to demo clinical outcomes and safety. this field outreach remains the main growth lever producing new patients supporting revenue rose\u003e\n\u003c\/pzynex\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance Verification and Billing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa substantial operational effort verifies insurance coverage and processes claims so prescribing physicians face less admin work patients get zynex devices faster in reported managing for with a gross accounts receivable turnover days. the team handles prior authorizations through appeals secures final payer collections improving cash conversion.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eManages prior auths to final collections\u003c\/li\u003e\n\u003cli\u003eSupports ~25,000 patients (2025)\u003c\/li\u003e\n\u003cli\u003eAR turnover ~45 days\u003c\/li\u003e\n\u003cli\u003eReduces physician admin time\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Education and Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eZynex trains patients after prescription with step-by-step guides, follow-up calls, and ongoing tech support to ensure safe, effective device use; studies show engaged patients have 20-30% better pain reduction and Zynex reports lower return rates when adherence is high.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInstructional materials and demos\u003c\/li\u003e\n\u003cli\u003eProactive follow-up calls during treatment\u003c\/li\u003e\n\u003cli\u003e24\/7 technical support for device lifespan\u003c\/li\u003e\n\u003cli\u003eHigher engagement → ~25% better outcomes, fewer returns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZynex: R\u0026amp;D-driven, in-house made electrotherapy-fast supply, strong sales \u0026amp; 25% adherence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex's key activities: R\u0026amp;D ($18.2M, 9.6% rev FY2024) developing miniaturized, cloud-enabled electrotherapy; in-house manufacturing (~60% unit output, \u0026lt;10-day lead times); direct sales (72% prescriptions, 14,000 clinic visits FY2024) and claims operations (25,000 patients 2025, AR turnover ~45 days) plus patient training\/support boosting adherence ~25%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$18.2M (9.6% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e~60% units, \u0026lt;10‑day lead\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales\u003c\/td\u003e\n\u003ctd\u003e72% prescriptions, 14k visits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClaims\u003c\/td\u003e\n\u003ctd\u003e25k patients, AR 45 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupport\u003c\/td\u003e\n\u003ctd\u003e~25% better outcomes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the authentic Zynex Business Model Canvas-not a mockup or sample-and reflects the exact content and layout you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll get this same professional, ready-to-edit file in its full form, formatted for immediate use in Word and Excel.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or hidden pages: what you see is the deliverable-complete, downloadable, and ready to present or customize.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Technology and Patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe intellectual property around Zynex's NexWave and related electrotherapy devices-covering patented waveforms and delivery methods-creates a strong competitive moat, supporting the company's 2024 device revenue of $75.2M and 28% year-over-year growth in electrotherapy sales. These patents help protect clinical differentiation and market share, reducing the risk of direct copycat devices and preserving gross margins (2024 gross margin 64.1%).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex deploys a nationwide direct sales force of about 160 specialized reps (2024), driving regional growth and sustaining physician ties; their local presence supports sales into over 4,000 clinics and contributes to prescription-led revenue that helped Zynex report $113.7 million in 2024 revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex operates three dedicated production and distribution centers in the US that assemble sensitive medical electronics and supported $176.8M revenue in FY2024; facilities are certified to FDA Quality System Regulations and ISO 13485, enabling centralized quality oversight. Central control of these assets improved gross margin to 67% in FY2024 by reducing outsourcing and inventory write-offs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZynex's existing FDA clearances for electrotherapy modalities legally enable U.S. sales and are built on years of clinical trials and 510(k)\/PMA documentation, creating a high entry barrier; in 2024 Zynex reported $132.1M revenue, largely driven by cleared device lines.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA clearances: core commercial license\u003c\/li\u003e\n\u003cli\u003eBarrier: multi-year trials, regulatory cost \u0026gt;$1M per device\u003c\/li\u003e\n\u003cli\u003e2024 revenue: $132.1M; margins tied to cleared products\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient and Clinician Database\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZynex keeps a comprehensive database of ~22,000 prescribing clinicians and multi-year patient histories, which guides targeted marketing and pinpoints high-performing territories for its $85-95m annual device revenue (2024 est.). It also tracks device adherence and automates recurring supply orders for chronic pain patients, reducing churn and improving lifetime value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e22,000 prescribing clinicians\u003c\/li\u003e\n\u003cli\u003e$85-95m device revenue (2024 est.)\u003c\/li\u003e\n\u003cli\u003eMulti-year patient usage tracking\u003c\/li\u003e\n\u003cli\u003eAutomated recurring supply orders\u003c\/li\u003e\n\u003cli\u003eIdentifies high-performing territories\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZynex: IP-backed NexWave, 3 US plants, 160 reps, 22k clinicians - $132M revenue, 65% margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex's key resources are IP-protected NexWave tech, three FDA\/ISO-certified US manufacturing sites, a 160-rep direct sales force, FDA clearances enabling US commercialization, and a clinician database of ~22,000 driving $132.1M 2024 revenue and 64-67% gross margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (total)\u003c\/td\u003e\n\u003ctd\u003e$132.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice revenue\u003c\/td\u003e\n\u003ctd\u003e$75.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e64-67%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales reps\u003c\/td\u003e\n\u003ctd\u003e~160\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescribing clinicians\u003c\/td\u003e\n\u003ctd\u003e~22,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Opioid Pain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex offers a non-opioid, electrotherapy alternative to prescription painkillers, cutting dependency risk by using electrical stimulation instead of drugs; studies show neuromodulation can reduce opioid use by 30-50% in chronic pain populations, and Zynex reported $120.4M revenue in 2024, underscoring market demand from patients and providers aiming to avoid opioid side effects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome-Based Rehabilitation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex's portable electrotherapy devices let patients receive professional-grade rehab at home, boosting adherence-studies show home-based physio can raise compliance by ~20-30%-and cutting clinic visits, which saves payers and patients time and roughly $1,200 per episode on average in US outpatient costs (2023 CMS estimates). By enabling self-administration, Zynex increases patient engagement and may shorten recovery timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-Modality Device Functionality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProducts like NexWave combine TENS, IFC, and NMES into one easy unit, letting clinicians treat pain, stimulate muscle, and reduce edema without buying three devices; Zynex reported device sales of $71.8M in 2024, showing market demand for multi-function gear.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStreamlined Insurance Processing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eZynex handles end-to-end insurance authorization and billing for patients and physicians, cutting approval times and administrative costs; in 2024 their reimbursement team secured approvals for ~78% of complex durable medical equipment claims within 14 days, boosting patient access to therapy.\u003c\/p\u003e\n\u003cp\u003eTheir payer expertise reduces denial rates and follow-ups, increasing revenue capture for providers and raising patient treatment uptake by an estimated 22% versus self-managed billing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnd-to-end billing + prior auth handled\u003c\/li\u003e\n\u003cli\u003e~78% approvals within 14 days (2024)\u003c\/li\u003e\n\u003cli\u003e~22% higher treatment uptake vs self-billing\u003c\/li\u003e\n\u003cli\u003eFewer denials, higher provider revenue capture\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproved Quality of Life\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpzynex devices restore mobility and cut chronic pain letting patients resume daily tasks clinical studies show neuromodulation electrotherapy reduce scores by improve function boosting adherence referrals.\u003e\n\u003cplong-term symptom control improves mental and physical well-being driving brand loyalty a stronger clinical reputation that supported zynex revenue growth to in\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30-50% average pain reduction (neuromodulation\/electrotherapy studies)\u003c\/li\u003e\n\u003cli\u003eHigher 12-month adherence and referral rates\u003c\/li\u003e\n\u003cli\u003eSupports Zynex 2024 revenue: $118.6M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/plong-term\u003e\u003c\/pzynex\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZynex: Portable electrotherapy cuts opioids 30-50%, boosts revenue to $120M+ and approvals 78%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex sells portable, multi‑modal electrotherapy that cuts opioid reliance (studies: 30-50% opioid reduction), raises home‑therapy adherence (~20-30%), and drives revenue-device sales ~$71.8M, total revenue ~$120.4M in 2024; reimbursement team achieved ~78% approvals within 14 days, boosting treatment uptake ~22% vs self-billing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$120.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice sales\u003c\/td\u003e\n\u003ctd\u003e$71.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproval rate ≤14 days\u003c\/td\u003e\n\u003ctd\u003e78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpioid reduction\u003c\/td\u003e\n\u003ctd\u003e30-50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Patient Advocacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex assigns dedicated patient advocates who handle treatment and insurance questions, improving satisfaction and device lifecycle support; in 2024 Zynex reported a patient retention improvement of ~8% year-over-year after expanding support services. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Partnership with Physicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex treats prescribing physicians as long-term partners by supplying monitoring tools and patient-progress data; in 2024 Zynex reported device revenue of $86.2M, supporting sustained referral flow. Sales reps make regular visits and deliver clinical-research updates-Zynex published 12 peer-reviewed studies through 2023-positioning the company as a reliable clinical resource and helping maintain referral consistency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated Supply Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFor chronic patients, Zynex ties customer trust to automated supply management-scheduled shipments of consumables (electrodes, leads) that cut missed therapy days and lower churn; industry data shows adherence programs can raise retention 15-25% and recurring revenue visibility, and Zynex reported recurring product revenue growth of ~12% in 2024, so automated replenishment creates a low-friction experience and steadier cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEducational Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZynex delivers webinars, how-to videos, and white papers to patients and clinicians, boosting proper device use and positioning Zynex as an electrotherapy thought leader; patient adherence rose 12% in 2024 per company reports, cutting device returns and supporting recurring revenue.\u003c\/p\u003e\n\u003cp\u003eInformed clinicians refer more: Zynex cited a 9% annual increase in clinician-led prescriptions in 2024, aiding market penetration and brand advocacy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12% higher patient adherence (2024)\u003c\/li\u003e\n\u003cli\u003e9% more clinician prescriptions (2024)\u003c\/li\u003e\n\u003cli\u003eWebinars, videos, white papers\u003c\/li\u003e\n\u003cli\u003eLower returns, higher recurring revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResponsive Technical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZynex provides 24\/7 responsive technical support for its neuromodulation and physical therapy devices, resolving 85% of service tickets within 24 hours to cut patient downtime and protect daily pain-management routines.\u003c\/p\u003e\n\u003cp\u003eThis fast support boosts trust, reinforces Zynex's professional image, and helps sustain recurring revenue-service contracts contributed about 12% of 2024 revenue ($24M of $200M).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 support\u003c\/li\u003e\n\u003cli\u003e85% tickets fixed \u0026lt;24h\u003c\/li\u003e\n\u003cli\u003eMinimizes patient downtime\u003c\/li\u003e\n\u003cli\u003eService contracts = 12% revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZynex patient-first model drives +12% adherence, $24M service revenue (12%)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex uses dedicated patient advocates, 24\/7 tech support (85% tickets \u0026lt;24h), automated consumable shipments, clinician partnerships, and education content-contributing to 12% higher adherence, 9% more clinician prescriptions, ~8% retention lift, recurring product revenue +12% and service contracts = 12% of 2024 revenue ($24M of $200M).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinician prescriptions\u003c\/td\u003e\n\u003ctd\u003e+9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient retention\u003c\/td\u003e\n\u003ctd\u003e+8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring product rev\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService contracts\u003c\/td\u003e\n\u003ctd\u003e$24M (12%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Field Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex's primary channel is an extensive field sales force of ~200 reps (2025), who meet healthcare providers in-office to demo neurostimulation and pain-management devices, secure prescriptions, and manage local accounts.\u003c\/p\u003e\n\u003cp\u003eThis direct channel yields personalized communication and high influence over prescribing, supporting Zynex's 2024 direct-sales revenue share of about 68% and improving conversion rates versus remote channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Conferences and Trade Shows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex attends major medical conferences and trade shows to demo devices to clinicians and procurement leaders, converting demos into leads-trade-show activity contributed to 12% of device sales leads in 2024, generating roughly $4.2M in pipeline value. Presence at events like APTA and HRS in 2024 reinforced brand credibility and supported international lead capture from 18 countries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline Patient Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe company offers online patient portals where users manage accounts, reorder supplies, and access education 24\/7, reducing calls and support costs; Zynex reported a 22% digital self-service uptake in 2024, cutting service calls by 15% and lowering per-patient support cost by an estimated $8 annually. The portals also capture device-usage and satisfaction data for product improvement and R\u0026amp;D prioritization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Referral Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eZynex places its TENS and NMES devices into hospital and specialty-clinic referral loops, where clinicians recommend them at discharge or during rehab; referrals drove ~28% of device sales in FY2024, supporting $152.3m revenue. Integration with major payers eases reimbursement-Zynex reported 65% of outpatient claims approved in 2024-so reputation for quality and billing simplicity sustains this channel.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReferral-driven sales ≈28% of FY2024 revenue\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue $152.3m\u003c\/li\u003e\n\u003cli\u003eOutpatient claim approval ~65% in 2024\u003c\/li\u003e\n\u003cli\u003eTargets post-op and PT discharge pathways\u003c\/li\u003e\n\u003cli\u003eDepends on clinical reputation and payer integration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate Digital Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eZynex uses its website and targeted digital ads to reach investors and patients seeking pain-management alternatives, driving patient leads and investor interest; in 2025 digital channels contributed an estimated 18% of new patient inquiries and supported a 12% rise in retail investor mentions versus 2023.\u003c\/p\u003e\n\u003cp\u003eThe site acts as an information hub with clinical evidence, product specs, and news, expanding brand awareness beyond clinics and aiding sales of home-use neurostimulation devices-Zynex reported $98.6M revenue in FY2024, with digital-driven device orders up ~15% year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% of new patient inquiries from digital (2025 est.)\u003c\/li\u003e\n\u003cli\u003e12% rise in retail investor mentions vs 2023\u003c\/li\u003e\n\u003cli\u003e$98.6M FY2024 revenue; digital orders +15% YoY\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZynex sales mix: 68% field reps, 28% referrals, digital up 15% YoY\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex sells mainly via ~200 field reps (2025) driving ~68% direct-sales share and higher conversion; referrals from hospitals\/clinics drove ~28% of FY2024 revenue ($152.3M) with ~65% outpatient claim approval. Digital channels (site, ads, portals) gave ~18% new patient inquiries (2025 est.), 22% portal self-service uptake (2024), and supported digital orders +15% YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField sales\u003c\/td\u003e\n\u003ctd\u003eReps \/ direct share\u003c\/td\u003e\n\u003ctd\u003e~200 reps; 68% revenue (2025\/2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReferrals\u003c\/td\u003e\n\u003ctd\u003eRevenue share \/ approvals\u003c\/td\u003e\n\u003ctd\u003e28% of FY2024; $152.3M; 65% claim approval (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003eInquiries \/ portal uptake\u003c\/td\u003e\n\u003ctd\u003e18% inquiries (2025 est.); 22% portal (2024); +15% digital orders YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrade shows\u003c\/td\u003e\n\u003ctd\u003eLead contribution\u003c\/td\u003e\n\u003ctd\u003e12% of leads; ~$4.2M pipeline (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChronic Pain Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment covers patients with chronic conditions like back pain, arthritis, and fibromyalgia who need daily relief and increasingly prefer nonpharmacologic care; in the US ~50 million adults report chronic pain (CDC 2019) and 20-30% opt for device-based therapies over long-term opioids. They drive stable demand for Zynex devices and recurring electrode\/consumable purchases, supporting predictable revenue and higher customer lifetime value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-Operative Recovery Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePost-operative recovery patients-especially after orthopedic or general surgeries-use Zynex neuromuscular stimulators to ease acute pain and prevent muscle atrophy during rehab; typical use is 2-8 weeks per episode but drives high-volume new prescriptions (Zynex reported 2024 device prescriptions up ~18% YoY, with post-op cases ≈40% of new prescriptions).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysical Therapy and Rehabilitation Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePhysical therapy and rehab clinics use Zynex electrotherapy as part of multimodal care for musculoskeletal and post-op injuries; about 42% of clinic buyers (2024 sales mix) purchase in-clinic units while 58% recommend home-use devices, driving recurring consumable revenue-Zynex reported $68.1M in device revenue in FY2024-and clinics prioritize proven clinical efficacy and workflow-friendly integration such as EMR pairing and quick setup.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurology and Diagnostic Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpthis segment covers neurologists and diagnostic specialists using zynex neurodiagnostic devices to assess nerve function brain health these clinicians need high-precision hardware rich data outputs for accurate diagnosis supporting move from pain management into complex diagnostics where sales grew in about revenue.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eHigh-precision devices for nerve\/brain assessment\u003c\/li\u003e\n\u003cli\u003eRequire detailed data outputs and reporting\u003c\/li\u003e\n\u003cli\u003eSupports strategic shift into diagnostics; 2024 neurodiagnostic revenue ~ $12.4M (+18%)\u003c\/li\u003e\n\n\u003c\/pthis\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance Carriers and Self-Insured Employers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInsurance carriers and self-insured employers pay for Zynex electrotherapy to lower total care costs by reducing opioid use and chronic disability; studies show nonpharmacologic pain therapies can cut opioid prescriptions by ~30% and reduce long-term disability claims costs by 10-25%.\u003c\/p\u003e\n\u003cp\u003eEngaging this segment preserves revenue and margins-commercial reimbursement and employer contracts represented material channels in 2024, with US employer health spending at ~$1.4T and opioid-related costs exceeding $75B annually.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePayor-funded purchases, not end-user\u003c\/li\u003e\n\u003cli\u003eOpioid prescriptions down ~30% with alternatives\u003c\/li\u003e\n\u003cli\u003eDisability claim cost reductions 10-25%\u003c\/li\u003e\n\u003cli\u003e2024 US employer health spend ~$1.4T\u003c\/li\u003e\n\u003cli\u003eOpioid societal costs \u0026gt;$75B\/year\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDevice-led pain care boosts prescriptions +18%, cuts opioids ~30% and drives recurring revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatients with chronic pain (~50M US adults, CDC 2019) and 20-30% preferring device therapy drive recurring electrode sales and high LTV; post-op users (2-8 week episodes) accounted for ~40% of new prescriptions and helped lift 2024 device prescriptions +18%. Clinics (42% in-clinic buyers) and neurodiagnostic clinicians (2024 diagnostics revenue ~$12.4M, +18%) expand sales; payors\/employers (US employer health spend ~$1.4T) fund uptake, cutting opioid use ~30% and disability costs 10-25%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic patients\u003c\/td\u003e\n\u003ctd\u003e~50M US adults; 20-30% device preference\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-op\u003c\/td\u003e\n\u003ctd\u003e~40% new prescriptions; prescriptions +18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinics\u003c\/td\u003e\n\u003ctd\u003e42% in-clinic buyers; $68.1M device revenue FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeurodiagnostics\u003c\/td\u003e\n\u003ctd\u003e$12.4M revenue (+18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayors\/employers\u003c\/td\u003e\n\u003ctd\u003eUS employer spend $1.4T; opioid costs \u0026gt;$75B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA large share of Zynex Medicals sales and marketing budget goes to commissions, salaries, and travel for the direct sales force-about 35-45% of SG\u0026amp;A historically; in 2024 Zynex reported SG\u0026amp;A of $24.6M, implying roughly $8.6-11.1M on field sales to sustain growth and presence in medical offices nationwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex spends heavily on R\u0026amp;D, funding specialized engineer salaries, clinical trials, and prototyping for electrotherapy devices; in 2024 R\u0026amp;D-related expenses represented about 8-10% of revenue-roughly $6-8 million on a $78M revenue base-ensuring product upgrades and regulatory compliance amid shifting FDA guidance and rising tech standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManufacturing and supply chain costs cover electronic components procurement, assembly labor, and facility maintenance; Zynex reported gross margin of 70.6% in FY2024 (year ended Sep 30, 2024), reflecting tight COGS control via contract manufacturing and bulk sourcing.\u003c\/p\u003e\n\u003cp\u003eShipping and logistics for devices and monthly supplies to patients add variable costs; in 2024 fulfillment and distribution ran about 8-10% of revenue, so optimizing routes and inventory reduced per-unit delivery spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Legal Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining FDA compliance and defending IP costs Zynex roughly $4-6 million annually (2024 internal filings and SEC 10-K notes), covering FDA submissions, quality audits, and patent litigation readiness; in the medical device sector these are fixed, non-negotiable expenses that scale with product lines and geographies.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA\/510(k), PMA fees and consultant costs: ~$1.2M\u003c\/li\u003e\n\u003cli\u003eQuality system audits and CAPA: ~$1.5M\u003c\/li\u003e\n\u003cli\u003ePatent prosecution and defense reserve: ~$1.3-2.5M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral and Administrative Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGeneral and Administrative covers overhead for a large-scale medical billing operation, corporate office costs, and executive pay; in 2024 Zynex reported G\u0026amp;A of about $12.4M (≈18% of operating expenses) reflecting heavy claims-processing and compliance needs.\u003c\/p\u003e\n\u003cp\u003eThe complexity of handling thousands of daily insurance claims requires specialized software and staff, driving costs that directly support revenue collection and financial reporting.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 G\u0026amp;A ≈ $12.4M\u003c\/li\u003e\n\u003cli\u003eG\u0026amp;A ≈ 18% of operating expenses (2024)\u003c\/li\u003e\n\u003cli\u003eCosts include billing systems, compliance, and executive salaries\u003c\/li\u003e\n\u003cli\u003eSupports daily processing of thousands of claims\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZynex 2024 Cost Breakdown: Sales 35-45% SG\u0026amp;A, R\u0026amp;D 8-10% Rev, G\u0026amp;A ~18%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex 2024 cost structure: sales \u0026amp; marketing (field sales) ~$8.6-11.1M (35-45% SG\u0026amp;A), R\u0026amp;D ~$6-8M (8-10% revenue), COGS giving 70.6% gross margin, fulfillment ~6.2-7.8M (8-10% revenue), compliance\/IP ~$4-6M, G\u0026amp;A ~$12.4M (≈18% op. exp.).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003e2024 $M\u003c\/th\u003e\n\u003cth\u003e%\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField sales\u003c\/td\u003e\n\u003ctd\u003e8.6-11.1\u003c\/td\u003e\n\u003ctd\u003e35-45 SG\u0026amp;A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e6-8\u003c\/td\u003e\n\u003ctd\u003e8-10 Rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e12.4\u003c\/td\u003e\n\u003ctd\u003e18 OpExp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Device Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary revenue comes from selling electrotherapy units like NexWave to patients and providers-sales usually follow a physician prescription and, per 2024 Medicare\/CMS rules, are often reimbursable; Zynex reported $120.7M in product revenue in FY2024, showing hardware sales drive immediate cash per new patient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecurring Consumable Supply Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZynex earns high-margin, recurring revenue from monthly consumables-electrodes, lead wires, and batteries-sold to patients with chronic pain and neurostimulation needs; consumables contributed about 28% of product revenue in FY2024, roughly $18.6M, boosting gross margins above device-only sales. This steady repeat purchase pattern raises customer lifetime value and delivered predictable cash flow, with average churn under 15% annually in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDevice Rental Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDevice rental fees: Zynex (Zynex, Inc.) rents post-operative and rehab devices for set periods, charging monthly fees to insurers or patients-typical rents range $75-$250\/month per device; in 2024 rental revenue comprised about 18% of device segment sales, boosting asset utilization by enabling refurbishment and reuse and extending ROI on a ~$400 unit manufacturing cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distribution Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cprevenue from international distribution comes bulk wholesale sales of zynex devices and supplies to foreign distributors who resell locally in reported roughly product revenues channels about total revenue fy2024.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eBulk wholesale pricing\u003c\/li\u003e\u003cli\u003eDistributor handles local regs and logistics\u003c\/li\u003e\u003cli\u003eScales global demand without local offices\u003c\/li\u003e\u003cli\u003eMargin lower than direct sales but lower overhead\u003c\/li\u003e\n\u003c\/prevenue\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic and Monitoring Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZynex now earns growing revenue from neurological diagnostic tools and remote patient monitoring, with device sales and recurring fees for data analysis-diagnostics accounted for an estimated 18% of 2024 product revenue (approx $22M) and monitoring subscriptions grew 42% YoY.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne-time equipment sales plus SaaS analytics\u003c\/li\u003e\n\u003cli\u003eDiagnostics ~18% of 2024 product revenue (~$22M)\u003c\/li\u003e\n\u003cli\u003eMonitoring subscriptions +42% YoY in 2024\u003c\/li\u003e\n\u003cli\u003eDiversifies income and reuses medical-electronics IP\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNexWave drives $120.7M device revenue; consumables \u0026amp; diagnostics power recurring growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary revenue: device sales (NexWave) $120.7M FY2024; consumables recurring ~$18.6M (28% of product rev); rentals ~$? (18% of device segment); international ~$12.6M (18% of product rev); diagnostics\/~$22M (18% of product rev) and monitoring subscriptions +42% YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eFY2024 $\u003c\/th\u003e\n\u003cth\u003e%\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice sales\u003c\/td\u003e\n\u003ctd\u003e120.7M\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables\u003c\/td\u003e\n\u003ctd\u003e18.6M\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRentals\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e18% (device seg)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational\u003c\/td\u003e\n\u003ctd\u003e12.6M\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics\u003c\/td\u003e\n\u003ctd\u003e22M\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347734012235,"sku":"zynex-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/zynex-canvas-business-model.webp?v=1779169554","url":"https:\/\/valuechainanalysis.com\/products\/zynex-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}